Geron Corporation (NASDAQ:GERN) will be posting its quarterly earnings results after the market closes on Wednesday, November 1st. Analysts expect Geron Corporation to post earnings of ($0.05) per share for the quarter.
Geron Corporation (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.38 million. Geron Corporation had a negative net margin of 433.72% and a negative return on equity of 21.30%. The firm’s revenue for the quarter was down 19.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.05) earnings per share. On average, analysts expect Geron Corporation to post $-0.18 EPS for the current fiscal year and $-0.02 EPS for the next fiscal year.
Geron Corporation (NASDAQ:GERN) traded up 0.728% during trading on Monday, reaching $2.075. 390,517 shares of the company traded hands. Geron Corporation has a 52 week low of $1.81 and a 52 week high of $3.15. The company’s 50-day moving average price is $2.15 and its 200 day moving average price is $2.47. The firm’s market capitalization is $330.37 million.
A number of equities analysts have weighed in on GERN shares. Zacks Investment Research raised Geron Corporation from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research report on Tuesday, October 3rd. FBR & Co reissued a “buy” rating on shares of Geron Corporation in a research report on Tuesday, July 4th. Finally, BidaskClub lowered shares of Geron Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $3.75.
Geron Corporation Company Profile
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
What are top analysts saying about Geron Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Geron Corporation and related companies.